Top Markets
#1 Ontology Gas Ontology Gas +45.91%
#2 Verus Coin Verus Coin +22.51%
#3 EXOD EXOD +22.08%
#4 Status Status +19.78%
#5 ETHGas ETHGas +18.84%
#6 Geodnet Geodnet +16.73%
#7 The Black Bull The Black Bull +16.27%
#8 Derive Derive +11.24%
#9 Fake World Assets Fake World Assets +11.05%
#10 Gas Gas +9.27%
Coin of the day
Ontology Gas Ontology Gas
設定
言語
日本
通貨
USD
テーマ
Promore Pharma AB (publ) Promore Pharma AB (publ)

Promore Pharma AB (publ)

PROMO
株式のランク #25506
Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to... Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to advancing peptide-based drug therapies. The company's development pipeline features PXL01, currently undergoing Phase IIa studies for its potential in preventing post-surgical adhesions and scars, mitigating dermal scarring, and aiding hand tendon repair. Another key asset, LL-37, is engaged in Phase IIb clinical trials to address venous leg ulcers, stimulate the healing of persistent wounds, and treat diabetic foot ulcers. Additionally, Promore Pharma has partnered with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. Founded in 2002, the company, formerly known as Lipopeptide AB until its rebranding in January 2017, maintains its headquarters in Solna, Sweden.
株価
$1.34
最終同期: 2024-02-14
時価総額
$48.96M
変化（1日）
-12.94%
変化（1年）
0.00%
国
SE
取引 Promore Pharma AB (publ) (PROMO)

カテゴリー

Healthcare
Promore Pharma AB (publ)（PROMO）のP/S比率
2026 時点のP/S比率 TTM: 0
Promore Pharma AB (publ) の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
Promore Pharma AB (publ) の P/S 比率の履歴（2026 ～ 2026）
各年末時点のP/S比率
年 P/S比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/S比率
企業 P/S比率 P/S比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US